Selective BTK Inhibitors for Lymphoma via Structural Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BTK inhibitors, such as ibrutinib, exhibit strong inhibitory effects on kinases like EGFR, ITK, and TEC, leading to adverse reactions, highlighting the need for BTK inhibitors with high activity and selectivity for treating related diseases.
Innovation Solution
Development of a compound represented by formula (I) or its stereoisomer or pharmaceutically acceptable salt, with specific structural features that provide high BTK kinase inhibitory activity and selectivity, thereby minimizing effects on other kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If irreversible BTK inhibitors like ibrutinib are used to inhibit BTK activity, then anti-tumor and anti-inflammatory effects are achieved, but strong inhibitory effects on other kinases (EGFR, ITK, TEC) cause serious adverse reactions
Solution Approach 1:
The patent applies local quality by designing a BTK inhibitor with specific structural features (formula I) that create different binding characteristics at the BTK active site versus other kinase sites. The compound has high affinity for BTK due to specific interactions with Cys-481 and the ATP-binding pocket, while lacking optimal interactions with EGFR, ITK, and TEC kinases, thereby achieving selective inhibition.
Solution Approach 2:
The patent employs parameter changes by optimizing molecular parameters such as the substituent groups R1-R6, ring structures A-D, and linker regions in formula I to tune the binding affinity and selectivity. By adjusting these structural parameters, the compound achieves IC50 < 100 nM for BTK while maintaining significantly weaker activity against other kinases, thus resolving the contradiction between efficacy and selectivity.
2Reliability
If BTK inhibitors with strong activity are developed to effectively inhibit B cell proliferation, then therapeutic effect is improved, but selectivity against other kinases decreases leading to more adverse reactions
Solution Approach 1:
The patent applies segmentation by dividing the BTK inhibitor molecule into distinct functional segments in formula I: a heteroaryl core (rings A and B), substituent groups (R1-R6) that interact with specific BTK residues, and linker regions (L1, L2). This segmented design allows each portion to contribute specifically to BTK binding, with the core heteroaryl structure providing selectivity through unique interactions with BTK's Cys-481 and surrounding residues.
Solution Approach 2:
The patent employs asymmetry by designing an asymmetric molecular structure in formula I where the substitution patterns on rings A and B, along with the specific configurations of L1 and L2 linkers, create a non-symmetric geometry that complements the asymmetric ATP-binding pocket of BTK. This asymmetric design enhances selectivity by preventing optimal binding to the more symmetric or differently configured ATP pockets of other kinases.
Data Source
AI summary
Disclosed are a class of BTK kinase inhibitor compounds with a high activity and a high selectivity and the use thereof in the preparation of a drug for treating BTK target-related diseases. Specifically, disclosed are a compound shown as formula (I), and an isomer and a pharmaceutically acceptable salt thereof.